Analystreport

Phathom Pharmaceuticals (PHAT) had its price target raised by Guggenheim from $20.00 to $25.00. They now have a "buy" rating on the stock.

Phathom Pharmaceuticals, Inc.  (PHAT) 
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am Check Earnings Report